Dr. Priya Narang
MD, MPH
Board-certified endocrinologist; clinical interest in growth-hormone-axis peptides and metabolic signalling.
Who reviews the work.
Dr. Priya Narang is a board-certified endocrinologist with eleven years of clinical practice in academic and community endocrinology. She trained at the University of Edinburgh and completed her internal-medicine and endocrinology fellowships at Imperial College Healthcare NHS Trust. Her clinical interest sits at the intersection of growth-hormone-axis peptide research (tesamorelin, sermorelin, CJC-1295, ipamorelin), mitochondrial-derived peptides (MOTS-c), and the broader research-peptide evidence base. Dr. Narang reads every Pepvise review against the trial literature, the FDA / EMA labels, and her own clinical judgment on the gap between published mechanism and clinical applicability. She does not advise readers on what they should take; she advises Pepvise's editors on whether the review accurately represents the published evidence, the regulatory posture, and the clinically meaningful caveats. She holds no equity in any pharmaceutical or compounding-pharmacy company.
What Dr. reviews on this site.
- Growth-hormone-axis peptide reviews (Tesamorelin, Sermorelin, CJC-1295, Ipamorelin)
- Mitochondrial-derived peptide reviews (MOTS-c)
- Endocrinology-adjacent dimensions of the methodology v1.2 scorecard
- Methodology weighting on the human-data and safety dimensions